DermRay helps dermatology practices leverage the benefits of Xstrahl’s dual modality Radiant system to expand treatment options for NMSC. For more than a decade, radiation oncologists Ankit Agarwal, MD and David Greene, MD, at DermRay have been providing turnkey...
La radioterapia superficial y de ortovoltaje proporciona una opción de tratamiento eficaz para una amplia variedad de indicaciones médicas, incluidos el cáncer de piel no melanoma, algunas afecciones benignas e incluso cuidados paliativos. Únase a Xstrahl y al...
While SARRP is often used to investigate the effect of radiation therapy in preclinical oncology settings, it should be noted that the impact of radiation on normal tissues requires understanding and further research to mitigate both early and late effects. The use of...
The role of radiation in treating non-malignant diseases is currently undergoing an American Renaissance. Low-dose radiation therapy (LDRT) has been used successfully throughout the world for treating benign conditions for over a century, but its resurgence has been...
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the AOCD 2024 meeting, in Scottsdale, AZ. Radiant Aura is a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring. Visit Xstrahl at AOCD 2024, booth # 22 at the Westin Kierland from April 11-14, 2024.
Xstrahl's Medical Director, Dr. Richard Shaffer, recently spoke for a webinar hosted by Joint Pain Practice. He shares how low-dose radiotherapy can be used for osteoarthritis, and overviews the treatment process, risks, and efficacy. https://youtu.be/ab4iyfhN_L8...
In this webinar, Tom Murray of Hull University Teaching Hospitals presents on developing an internal eye shield for radiotherapy. Internal eye shields are a simple yet effective solution to protect the patient’s lenses during superficial and orthovoltage radiation...
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the Maui Derm Hawaii 2024 meeting, January 22-26, 2024. Radiant Aura is a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring.
Accurate dosimetry and reporting is the best practice in radiation research. While systems like the Xstrahl CIX series have been established as both reproducible and accurate, determining the exact dose delivered to a subject can be difficult due to the interactions...
Contact Us